Eiger BioPharmaceuticals (EIGR) Misses Q2 EPS by 8c

Eiger BioPharmaceuticals (NASDAQ: EIGR) reported Q2 EPS of ($0.47), $0.08 worse than the analyst estimate of ($0.39). Revenue for the quarter came in at $4.64 million versus the consensus estimate of $4.57 million.

For earnings history and earnings-related data on Eiger BioPharmaceuticals (EIGR) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Zeo Energy Corp (ZEO) Misses Q2 EPS by 7c
• Tvardi Therapeutics (TVRD) Tops Q2 EPS by 1c